{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000012","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.876296+00:00","generated_at":"2026-06-17T03:01:30.080085+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Travere Therapeutics dismisses BDO as auditor, appoints EY; discloses material weakness in internal controls","bullets":["BDO dismissed as independent auditor effective April 6, 2023; EY appointed for fiscal year ending Dec 31, 2023.","BDO's audit reports for FY2022 and FY2021 were unqualified with no adverse opinion or modifications.","Disclosed material weakness in controls over pre-launch inventory contract affecting R&D expense timing; no restatement required.","No disagreements with BDO on accounting principles or audit scope during 2022, 2021, or interim period through April 6, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000012","json":"https://secwatch.observer/filing/0001438533-23-000012.json","markdown":"https://secwatch.observer/filing/0001438533-23-000012.md","text":"https://secwatch.observer/filing/0001438533-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/tvtx-20230406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:01:30.080085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35dea603b04563fd81e0b601b01ef7b5da647fbb","claim":"Travere Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"the Audit Committee approved the appointment of EY as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"},{"claim_id":"82fca8ac06b922d167829617fee42dfcbea7c6e4","claim":"Travere Therapeutics, Inc. dismissed BDO USA, LLP as its auditor.","evidence_excerpt":"On April 6, 2023, the Audit Committee dismissed BDO as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000012/0001438533-23-000012-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"BDO USA, LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}